When Irvine California-based Axonics received FDA approval in September 2019 for its r-SNM system for fecal incontinence it not only became Medtronics sole competitor in the space but brought new capabilities as the first rechargeable version for patients while also being safe for patients to undergo full-body MRI scans. Patent and Trademark Offices Patent Trial and Appeal Board has decided to move forward in reviewing claims made by sacral neuromodulation specialist Axonics against Medtronic. Axonics Announce Positive Clinical Data From Its Artisan Sacral Neuromodulation Pivotal Study Evidence from clinical trials shows that Axonics SNM system improves symptoms of overactive bladder and quality of life. Axonics clinical trial . The RELAX-OAB Treatment of REfractory Overactive BLadder with the AXonics Sacral Neuromodulation System is a post-market clinical follow-up PMCF study designed to confirm the performance of the Axonics Sacral Neuromodulation SNM System as an aid in the trea